Media enquiries
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.
Do you have
any question?
29/04/2025
Medical Developments International enters licensing agreement for Penthrox® (methoxyflurane) distribution with Ethypharm in France
Saint-Cloud, France & Melbourne, Australia – 29 April 2025. Medical Developments International (ASX:
MVP) and Ethypharm have entered into a licensing agreement for marketing and distribution of Penthrox®
(methoxyflurane) in France.
Penthrox® is an inhaled analgesic used across multiple countries for acute pain management. Under this
agreement, Ethypharm will be responsible for the marketing and distribution of Penthrox® in France.
Transition planning has commenced, with Ethypharm expected to commence its commercial activities in
July 2025.
MVP’s CEO Brent MacGregor said, “Ethypharm’s existing portfolio and market presence is complimentary to Penthrox®. Ethypharm is well positioned to support Penthrox® distribution in the hospital segment. We are excited to begin this relationship with Ethypharm to support access to Penthrox® for people in need in France.”
Xavier Lasserre, Chief Operating Officer of Ethypharm, added: “At Ethypharm, we are committed to
providing healthcare professionals with effective solutions for the treatment of moderate to severe acute traumatic pain. Partnering with Medical Developments International to support the distribution of Penthrox® in France aligns perfectly with our mission to deliver essential medicines that help improve patient lives. We look forward to a successful collaboration.”